Credit: Novartis. The approval was based on data from the phase 3 APPLY-PNH trial. Health care providers who prescribe Fabhalta must enroll in the Fabhalta REMS. The Food and Drug Administration (FDA) ...
Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement ...
Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...
The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...
Iptacopan treatment on top of standard of care resulted in significant and clinically meaningful reductions in proteinuria compared with placebo in patients with complement 3 glomerulopathy. Results ...
Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 ...
Newcastle researchers have revealed the first treatment to target the underlying cause of a rare kidney condition called "C3G" and prevent the disease progressing. Publishing in The Lancet, the ...
Novartis (NYSE:NVS) reported detailed results from a phase 3 trial of its oral drug iptacopan to treat certain patients with paroxysmal nocturnal hemoglobinuria (PNH). The study, dubbed APPOINT-PNH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback